
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics is attractive because its lead TED franchise has already shown differentiated clinical performance, with veligrotug meeting pivotal endpoints and the launch of Lumvoa generating $24.7M in first-quarter net product revenue and more than 100 patients on therapy. The company also has a strong balance sheet, with $955.2M in cash, cash equivalents, and marketable securities, which supports operations through profitability while management invests in commercialization and pipeline expansion. Beyond TED, the -74% IgG reduction and favorable safety profile for VRDN-008, plus a planned pivotal study in mid-2027 and modeled FY31 revenue of $269M in its first four quarters, add meaningful diversification and longer-term upside.
Bears say
Viridian Therapeutics is exposed to substantial regulatory risk because accelerated approval strategies may still require additional data, longer studies, or revised requirements, and any label that lacks key features could weaken commercial adoption. Its outlook is also pressured by execution and competition, since underperformance could hurt shares while AMGN, IMVT, and private or generic rivals can shift sentiment in either direction. The company likely needs additional external funding to advance its development platform, and inability to access capital markets could delay or halt programs; if veligrotug fails on efficacy or safety in TED, the stock could trade near net cash with minimal pipeline value at $14/sh.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Viridian Therapeutics (VRDN) Forecast
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares